



May 31st, 2011

Session 1: Anaphylaxis versus acute infusion reactions provoked by therapeutic antibodies (13h30-15h30)

chair: Yvon Lebranchu

Infusion-related syndromes induced by monoclonals in onco-haematology (13h30-14h)

Philippe Solal-Céligny (Le Mans, France)

Acute infusion reactions in patients immunized to monoclonals (14h-14h30)

Enrico Maggi (Florence, Italy).

Cytokine storms: the TGN1412 case (14h30-15h)

Robin Thorpe (Biotherapeutics Group, UK)

Clinical manifestations and incidence of anaphylactic events during cetuximab treatment in France (15h-15h30)

Aurélie Grandvullemin (Dijon, France)

Charles Richet lecture (15h30-16h15)

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

Thomas Platts-Mills (Charlottesville, USA)

Break

Tours, France,
May 31st - June 1st 2011

Therapeutic Antibodies and Anaphylaxis

Anticorps Thérapeutiques et Anaphylaxie

Anaphylaxis among other acute reactions, role of anti-glycan antibodies and practical consequences for patients
L'anaphylaxie parmi les autres manifestations aiguës, rôle des anticorps anti-glycannes et conséquences pratiques pour les patients

Session 2: Glycans as targets of IgE and other natural antibodies, and their involvement in adverse reactions to therapeutic antibodies (16h45-18h45)

chair: Roy Jefferis

The natural anti-Gal antibody in evolution and in the clinic (16h45-17h15)

Uri Galili (Worcester, USA)

Factors influencing the production of anti-alphaGal IgE antibodies (17h15-17h45)

Yoann Pointreau (Tours, France)

The "Hanganutziu-Deicher antigen": a historical perspective (17h45-18h15)

Jean-François Bouhours (Nantes, France)

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic antibodies (18h15-18h45)

Ajit Varki (San Diego, USA).

Gala dinner in the Château of Villandry.

The recent history of this famous castle in the Loire Valley is linked to Charles Richet

June 1st, 2011

Session 3: Strategies to prevent cetuximab anaphylaxis in clinical practice (9h-12h)

chair: Philippe Solal-Céligny

Cetuximab glycosylation (9h-9h30)

Roy Jefferis (Birmingham, UK)

Development of CetuGEX™, a cetuximab “biobetter” (9h30-9h50)

Steffen Goletz (Glycotope, Heidelberg, Germany)

Premedication strategies to limit anaphylaxis to cetuximab, (9h50-10h10)

Johannes Blatter (Merck, Darmstadt, Germany)

Break

Skin testing to cetuximab (10h30-10h50)

Anne Moneret-Vautrin (Epinal, France)

New assays for the detection of anti-glycan IgE (10h50-11h10)

Anita Kober (Phadia, Uppsala, Sweden)

Predictive value of anti-cetuximab IgE antibodies (11h10-11h30)

Benoît Dupont (Caen, France)

Desensitization to cetuximab (11h30-11h50)

Maya Jerath (Chapel Hill, USA)

Final discussion, conclusion and end of meeting (11h50-12h)

Lunch

Localisation:

Université François-Rabelais :
Site des Tanneurs-Bâtiment Extension (Porte Z)
3, rue des Tanneurs. 37000 Tours.
Amphithéâtre 2 , 1^{er} étage

Registration fees * :

Student: 50 €

Academic Researcher : 75€

Companies: 300 €

*includes admission to scientific sessions, coffee breaks, lunch does not include transport , hotel or Gala dinner.

Gala dinner in the Château of Villandry: 60 €

Site Web:

<http://therabanaphyl.univ-tours.fr>

Under the auspices of :

